Licensing remains a dominant model. The value of the licensing-out deals signed by Chinese biotech firms in the first half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback